Do you want to volunteer for Clinical Trials? Register now

Advertise Your Study

To advertise your Clinical Trial with, please fill in the form below. If you have an online advertisement already, we can advertise the study and provide links to your own online registration form. Information provided below will form the basis of your study online brief. Alternatively, you can contact us.

Volunteers that apply directly to your study will not join the MedTrials "registered volunteers" list that is mailed out on monthly basis (unless they choose to do so).

Clinical Investigator Services

CRO’s, Pharmaceutical companies and Clinical Investigators have access to a number of services:

Recruit Volunteers for your Medical Trial offers access to our comprehensive database of candidates interested in taking part in Phase 1 Medical Trials.

Advertise your Medical Trial has been developed to ensure we have maximum exposure on the Internet. This creates a perfect platform for you to advertise your Clinical Trials to reach as many volunteers as possible.

Through intelligent website optimisation and effective advertising campaigns, we ensure that remains at the top of search engine listings on the Internet.

As a Clinical Research Organisation or Clinical Investigator you can either advertise your specific trail with us or you can search a ready made list of candidates that are interested in hearing more about studies that may be taking place in the future.

CRO’s, Pharmaceutical Companies and Clinical Investigators can advertise their medical trials on our searchable advertising board.

Access to volunteer database is an extensive current database of candidates interested in taking part in Phase I Medical Trials. Data collected includes contact details including address, phone and email together with data about the volunteer’s medical history.

Why should I advertise my Clinical Trial with MedTrials?

Difficulty recruiting? Additional resource to minimise delay in recruitment etc.

Relevant Applicants Instantly - has invested a large amount of advertising spend to ensure that we are consistently near the top of search engine listings. By using targeted, selective advertising methods, we ensure that only interested, relevant volunteers are attracted to our website. Massive online traffic to our website means that by advertising with MedTrials, you can access a large population of volunteers very quickly. You can also search the database for suitable candidates.

Simple Pricing, cost-effective - You will only be charged once for the price of each advert regardless of how many applicants you receive.


Reversing brain death: Far-fetched or feasible?

Ira Pastor, CEO of Bioquark, Inc., speaks to MNT about his team’s controversial plans to restore life to people who have been declared brain dead. Powered by WPeMatico

more >

Peanut allergy could be cured with probiotics

The vast majority of children in a large clinical trial continued to tolerate peanuts for 4 years after it had ended, new research shows. Powered by WPeMatico

more >

‘Accelerated approval’ drugs: How well are they studied?

When an investigational prescription drug shows promise for treating a serious illness or filling an unmet medical need, the Food and Drug Administration (FDA) has special programs available to… Powered by WPeMatico

more >

Prostate cancer: Study identifies earlier clinical trial endpoint that can be used to indicate effectiveness of new treatments

Scientists say they have validated a “surrogate endpoint” – a reliable statistical shortcut in a clinical trial – that could accelerate testing of new adjuvant therapies aimed at reducing deaths from… Powered by WPeMatico

more >

Alexion and Sema4 announce strategic partnership

Alexion Pharmaceuticals, Inc. and Sema4 have announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery. This new partnership will combine Alexion’s rare disease SmartPanel analytics with Sema4’s proven success in next-generation sequencing and genomic interpretation to further enable novel diagnostic and […]

more >

Galapagos announces phase IIa results with GLPG1690 in IPF patients

Galapagos NV has announced positive topline results with its autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF) in the FLORA phase IIa trial. FLORA was an exploratory, randomized, double-blind, placebo-controlled trial investigating a once-daily oral dose of GLPG1690. The drug candidate was administered for 12 weeks in 23 IPF patients, 17 of whom received […]

more >